Clinical Trial Update: SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone [Phase 2]

View source ↗

Summary

Phase 2 SWITCH study evaluated switching from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients treated with abiraterone; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• DEXAMETHASONE (Dexamethasone)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED